Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2013005921
pages 177-195

Causes of Death Due to Hematological and Non-Hematological Cancers in 57 US Patients with Type 1 Gaucher Disease Who Were Never Treated with Enzyme Replacement Therapy

Neal J. Weinreb
University Research Foundation for Lysosomal Storage Diseases, Boca Raton, Florida 33433, USA and the Dr. John T Macdonald Foundation, Department of Human Genetics at the University of Miami Miller School of Medicine, Miami, Florida, 33144, USA
Robert E. Lee
Department of Pathology (Emeritus), University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA

SINOPSIS

Patients with type 1 Gaucher disease (GD1) have increased risk of developing myeloma, other hematological cancers, hepatocellular carcinoma, and other solid tumors. Patient awareness of the GD1–cancer association causes anxiety and fear. Little is known about cancer as a cause of death in GD1, especially in patients never treated with GD1-specific therapies. Consequently, the effect of treatment on cancer mortality in GD1 patients is difficult to evaluate. In this review, starting with a population of 184 GD1 cases never treated, we annotate and analyze the causes of death of 57 GD1 patients who died of cancer. The proportional mortality ratio (PMR) for all malignancies in patients with GD1 is 1.57 (p = 0.0002), but it is much higher for myeloma (PMR = 9.66) and other hematological cancers, hepatocellular carcinoma, and kidney cancer (PMR = ≈4). However, deaths from colorectal and pancreatic cancers were not more frequent than expected, and deaths from lung, breast, gynecological, and prostate cancer occurred less than anticipated. Herein, we discuss whether GD1 is truly a hereditary cancer syndrome and the problem of comorbidities and cancer risk assessment, and we speculate as to whether the variability in death by cancer type might be attributable to biochemical sequelae of tumor cell and macrophage/stromal cell GBA1 mutation affecting signals for metastasis, the process most closely associated with cancer mortality.


Articles with similar content:

Predicting the Efficacy of 5-Fluorouracil–Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis
Journal of Environmental Pathology, Toxicology and Oncology, Vol.38, 2019, issue 1
Fangchao Zheng, Raees Ahmad, Xinyue Yuan, Ziyi Wang, Guoshuang Shen, Zhijun Ma, Dengfeng Ren, Fuxing Zhao, Jiuda Zhao
Relationship between Topoisomerase II Alpha Overexpression and Prognosis in Chinese Gastric Cancer Patients
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 3
Binghe Xu, Fangchao Zheng, Feng Du, Jinhua Ma, Fei Ma, Ziyi Wang, Junhui Zhao, Shuyan Wang, Wei Ma, Li Dong, Guoshuang Shen, Yang Luo, Cunfang Shen, Jiuda Zhao, Xinfu Ma
Commentary on Lynch Syndrome and Related Familial Colorectal Cancers
Critical Reviews™ in Oncogenesis, Vol.14, 2008, issue 1
Stephen J. Lanspa, Henry T. Lynch
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
James J. Morrow, Chand Khanna
Association between Epstein-Barr Virus and Oral Carcinoma: A Systematic Review with Meta-Analysis
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 4
Heberty Tarso Facundo, Cláudio Gleidiston Lima da Silva, Marcos Antonio Pereira de Lima, Fernanda de Morais Marques, Roberto Flávio Fontenelle Pinheiro Junior, Pedro Hugo Bezerra Maia Filho, Lara Eduardo de Galiza, Geamberg Einstein Cruz Macedo, Ilara Parente Pinheiro Teodoro, Marcos Venício Alves Lima